Results 11 to 20 of about 802 (167)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

Journal of Diabetes Investigation, 2020
Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Post marketing surveillance of selected veterinary medicines in Tanzania mainland

BMC Veterinary Research, 2022
Background Veterinary medicines have been widely used for the prevention and treatment of animal diseases. Globally, the veterinary medicine industry is growing.
Adam M. Fimbo, Betty A. Maganda, Kissa W. Mwamwitwa, Itikija E. Mwanga, Engelbert B. Mbekenga, Seth Kisenge, Sophia A. Mziray, Gerald S. Kulwa, Yonah H. Mwalwisi, Danstan H. Shewiyo   +9 more
doaj   +1 more source

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

Journal of Diabetes Investigation, 2019
Aims/Introduction The present study analysis was carried out to evaluate the safety and efficacy of tofogliflozin, a sodium–glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice.
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, Kohei Kaku   +9 more
doaj   +1 more source

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India

Human Vaccines & Immunotherapeutics, 2022
A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age.
Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella, Krishna Mohan Vadrevu   +5 more
doaj   +1 more source

Post-marketing safety surveillance of the rotavirus vaccine in India

Vaccine: X, 2023
Background: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India.
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Sajjad Desai, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni   +9 more
doaj   +1 more source

Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance

BMC Psychiatry, 2023
Background A post-marketing surveillance of blonanserin has been ongoing since September 2018. The aim of this study was to assess the effectiveness and safety of oral blonanserin in Chinese young and middle-aged female patients with schizophrenia in ...
Qijing Bo, Xijin Wang, Xuejun Liu, Hong Sang, Zhiyuan Xun, Ruiling Zhang, Xiaodong Yang, Huaili Deng, Keqing Li, Jindong Chen, Meijuan Sun, Guijun Zhao, Xianglai Liu, Duanfang Cai, Guilai Zhan, Juhong Li, Haiyun Li, Gang Wang   +17 more
doaj   +1 more source

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk

Osteoporosis and Sarcopenia, 2019
Objectives: To reassess the safety and efficacy of once-weekly teriparatide 56.5 μg in osteoporosis patients with a high fracture risk. Methods: This postmarketing observational study was conducted at 72 weeks according to the package insert. Of the 3573
Emiko Ifuku, Takeshi Yoshimura, Toyonobu Uzawa, Tadami Hokonohara   +3 more
doaj   +1 more source

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study

Drugs in R&D, 2019
Objectives Our objective was to investigate the effectiveness and safety of silodosin in patients with benign prostatic hyperplasia (BPH) who switched to silodosin from another α1 blocker because of inadequate response.
Hiroshi Takahashi, Shinichi Kubono, Takehiko Taneyama, Kiyotoshi Kuramoto, Hideki Mizutani, Noriko Tanaka, Masaki Yoshida   +6 more
doaj   +1 more source

Current status, and future prospects of pharmaco-epidemiology and post-marketing surveillance in Saudi Arabia: A review of literature

Saudi Pharmaceutical Journal, 2018
Background: Pharmacoepidemiology is the concept used for evaluating the impact of drugs among a large number of people in the post-marketing phase. The use of this concept makes it increasingly necessary to detect the recurrence of drug-related anomalies
Ashraf El-Metwally
doaj   +1 more source